FY2029 EPS Estimates for Pyxis Oncology Increased by Analyst

Pyxis Oncology, Inc. (NASDAQ:PYXS) – Analysts at HC Wainwright upped their FY2029 earnings per share (EPS) estimates for shares of Pyxis Oncology in a research report issued to clients and investors on Monday, November 10th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of $0.21 for the year, up from their previous forecast of $0.20. HC Wainwright currently has a “Buy” rating and a $5.00 price target on the stock. The consensus estimate for Pyxis Oncology’s current full-year earnings is ($1.04) per share.

Pyxis Oncology (NASDAQ:PYXS) last issued its earnings results on Monday, November 3rd. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.36) by $0.01.

A number of other research firms have also weighed in on PYXS. Stifel Nicolaus initiated coverage on shares of Pyxis Oncology in a report on Monday, November 3rd. They set a “buy” rating and a $9.00 target price on the stock. Guggenheim lifted their price target on shares of Pyxis Oncology from $5.00 to $7.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. Zacks Research downgraded Pyxis Oncology from a “strong-buy” rating to a “hold” rating in a report on Tuesday, November 4th. Wall Street Zen lowered Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Friday, October 3rd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Wednesday, October 8th. Four research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Pyxis Oncology currently has an average rating of “Hold” and an average target price of $7.25.

Pyxis Oncology Price Performance

Pyxis Oncology stock opened at $4.37 on Tuesday. The business has a 50 day moving average of $2.92 and a 200-day moving average of $1.79. The company has a market capitalization of $272.08 million, a P/E ratio of -2.73 and a beta of 1.41. Pyxis Oncology has a 1 year low of $0.83 and a 1 year high of $4.85.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in PYXS. Persistent Asset Partners Ltd acquired a new stake in Pyxis Oncology during the third quarter worth approximately $77,000. Vanguard Group Inc. boosted its holdings in shares of Pyxis Oncology by 0.7% during the 3rd quarter. Vanguard Group Inc. now owns 2,163,962 shares of the company’s stock worth $4,804,000 after buying an additional 14,566 shares in the last quarter. Bridgeway Capital Management LLC grew its position in shares of Pyxis Oncology by 76.1% during the 2nd quarter. Bridgeway Capital Management LLC now owns 142,295 shares of the company’s stock worth $157,000 after buying an additional 61,500 shares during the period. Jane Street Group LLC bought a new stake in shares of Pyxis Oncology in the 2nd quarter valued at $370,000. Finally, Velan Capital Investment Management LP acquired a new position in shares of Pyxis Oncology during the 2nd quarter valued at $44,000. 39.09% of the stock is owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.